Company: IMRX
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001790340-25-000135
Chunk: 339

Company: Immuneering Corp
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 339
---
 assets1,904,097 (1,183,785)Other assets802,848 (261,337)Increase (decrease) in:  Accounts payable(474,214)(168,884)Accrued expenses1,908,736 (581,135)Lease liabilities(246,528)(221,934)Other liabilities(153,576)(200,113)Net cash used in operating activities(35,503,997)(40,489,058)Cash flows from investing activities:  Purchases of property and equipment(18,316)(75,519)Purchases of marketable securities— (5,410,170)Maturities of marketable securities— 26,430,000 Net cash (used in) provided by investing activities(18,316)20,944,311 Cash flows from financing activities:  Proceeds from exercise of stock options138,700 732,458 Proceeds from issuance of common stock under employee stock purchase plan421,910 374,652 Proceeds from issuance of common stock under at-the-market offering, net of issuance costs15,020,046 4,237,397 Proceeds from sale of common stock, prefunded warrants and common stock warrants through private placement24,998,919 — Proceeds from public offering of common stock, net of commissions and underwriting164,500,006 — Proceeds from issuance of common stock through private placement with Aventis Inc25,000,000 — Payment of offering and placement costs(3,138,911)— Net cash provided by financing activities226,940,670 5,344,507 Net increase (decrease) in cash and cash equivalents191,418,357 (14,200,240)Cash and cash equivalents at beginning of period36,144,720 59,405,817 Cash and cash equivalents at end of period$227,563,077 $45,205,577 Supplemental disclosures of noncash information:  Offering and placement costs included in accounts payable/accrued expenses$845,933 $— 

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

11

Table of Contents

IMMUNEERING CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1 – Organization and Nature of Business